Kamada Ltd
NASDAQ:KMDA

Watchlist Manager
Kamada Ltd Logo
Kamada Ltd
NASDAQ:KMDA
Watchlist
Price: 7.02 USD -0.14% Market Closed
Market Cap: 404.9m USD
Section:
 

Relative Value

The Relative Value of one KMDA stock under the Base Case scenario is hidden USD. Compared to the current market price of 7.02 USD, Kamada Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KMDA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.3
P/S
P/S
Price to Sales
2.3
vs History
26
vs Industry
74
Median 3Y
2.1
Median 5Y
2.1
Industry
7.9
Forward
2.2
More Details
19.8
P/E
P/E
Price to Earnings
19.8
vs History
44
vs Industry
6
Median 3Y
21.8
Median 5Y
19
Industry
24
Forward
19.1
More Details
14.3
P/OCF
P/OCF
Price to OCF
14.3
vs History
38
vs Industry
14
Median 3Y
12.1
Median 5Y
11.9
Industry
21.6
More Details
36.2
P/FCFE
P/FCFE
Price to FCFE
36.2
vs History
14
vs Industry
9
Median 3Y
13.8
Median 5Y
15.4
Industry
23.7
More Details
1.5
P/B
P/B
Price to Book Value
1.5
vs History
15
vs Industry
48
Median 3Y
1.3
Median 5Y
1.3
Industry
3.4
More Details
2
EV/S
EV/S
Enterprise Value to Sales
2
vs History
22
vs Industry
66
Median 3Y
1.7
Median 5Y
1.7
Industry
8.3
Forward
1.9
More Details
4.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.5
vs History
38
vs Industry
57
Median 3Y
4.3
Median 5Y
4.3
Industry
10.3
More Details
8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8
vs History
73
vs Industry
12
Median 3Y
9.3
Median 5Y
9.3
Industry
6.7
Forward
7.7
More Details
12.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.3
vs History
57
vs Industry
8
Median 3Y
15.8
Median 5Y
13.5
Industry
7.2
Forward
11.6
More Details
12.1
EV/OCF
EV/OCF
Enterprise Value to OCF
12.1
vs History
34
vs Industry
14
Median 3Y
11
Median 5Y
9.7
Industry
8.2
More Details
18.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
18.7
vs History
30
vs Industry
10
Median 3Y
12.3
Median 5Y
12.1
Industry
6.7
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
26
vs Industry
53
Median 3Y
1
Median 5Y
1
Industry
5.7
More Details

Multiples Across Competitors

KMDA Competitors Multiples
Kamada Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
Kamada Ltd
NASDAQ:KMDA
404.9m USD 2.3 19.8 8 12.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 794 036.5 -160 618 -195 041.5 -192 815.9
US
Abbvie Inc
NYSE:ABBV
395.9B USD 6.6 168.6 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
170.8B USD 4.7 24.4 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
153B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.3B USD 9.7 30.8 22.6 23.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.7 -531.9 -579.2 -563.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD 5.5 17.2 16.3 18.5
AU
CSL Ltd
ASX:CSL
88.2B AUD 3.8 19.6 13.2 16.4
NL
argenx SE
XBRU:ARGX
46.3B EUR 15.1 35.4 61.3 63
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54.4B USD 16.9 1 248.3 164.2 199.1
P/S Multiple
Revenue Growth P/S to Growth
IL
Kamada Ltd
NASDAQ:KMDA
Average P/S: 3 072 381
2.3
10%
0.2
FR
Pharnext SCA
OTC:PNEXF
33 794 036.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
10%
1
US
E
Epizyme Inc
F:EPE
2 084.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.1
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.9
46%
0.4
P/E Multiple
Earnings Growth PEG
IL
Kamada Ltd
NASDAQ:KMDA
Average P/E: 175.9
19.8
28%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 618 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.8
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
19.6
11%
1.8
NL
argenx SE
XBRU:ARGX
35.4
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 248.3
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IL
Kamada Ltd
NASDAQ:KMDA
Average EV/EBITDA: 36.9
8
11%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 041.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
11%
1.5
AU
CSL Ltd
ASX:CSL
13.2
8%
1.6
NL
argenx SE
XBRU:ARGX
61.3
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
164.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IL
Kamada Ltd
NASDAQ:KMDA
Average EV/EBIT: 42.9
12.3
27%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 815.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
AU
CSL Ltd
ASX:CSL
16.4
11%
1.5
NL
argenx SE
XBRU:ARGX
63
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
199.1
N/A N/A

See Also

Summary
KMDA intrinsic value, competitors valuation, and company profile.
DCF Valuation
KMDA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KMDA stock valuation using valuation multiples.
Wall Street Estimates
KMDA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KMDA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.